For help on how to get the results you want, see our search tips.
385 results
Medicine
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Paediatric investigation plans Remove Paediatric investigation plans filter
Medicine type
Orphan medicine Remove Orphan medicine filter
Additional monitoring Remove Additional monitoring filter
Authorisation status
Authorised Remove Authorised filter
-
List item
Human medicine European public assessment report (EPAR): Obizur (updated)
susoctocog alfa, Hemophilia A
Date of authorisation: 11/11/2015,
, 
, Revision: 11, Authorised, Last updated: 20/11/2023
-
List item
Human medicine European public assessment report (EPAR): Vimizim (updated)
recombinant human n-acetylgalactosamine-6-sulfatase, Mucopolysaccharidosis IV
Date of authorisation: 27/04/2014,, 
, Revision: 13, Authorised, Last updated: 20/11/2023
-
List item
Human medicine European public assessment report (EPAR): Imfinzi (updated)
durvalumab, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 21/09/2018,, Revision: 18, Authorised, Last updated: 20/11/2023
-
List item
Human medicine European public assessment report (EPAR): Darzalex (updated)
Daratumumab, Multiple Myeloma
Date of authorisation: 20/05/2016,
, , Revision: 21, Authorised, Last updated: 20/11/2023
-
List item
Human medicine European public assessment report (EPAR): Ajovy (updated)
fremanezumab, Migraine Disorders
Date of authorisation: 28/03/2019,, Revision: 10, Authorised, Last updated: 20/11/2023
-
List item
Human medicine European public assessment report (EPAR): Jaypirca (updated)
pirtobrutinib, Lymphoma, Mantle-Cell
Date of authorisation: 30/10/2023,, 
, Authorised, Last updated: 20/11/2023
-
List item
Human medicine European public assessment report (EPAR): Leqvio (updated)
inclisiran, Hypercholesterolemia; Dyslipidemias
Date of authorisation: 09/12/2020,, Revision: 5, Authorised, Last updated: 20/11/2023
-
List item
Human medicine European public assessment report (EPAR): Wakix (updated)
pitolisant, Narcolepsy
Date of authorisation: 31/03/2016,, , Revision: 15, Authorised, Last updated: 20/11/2023
-
List item
Human medicine European public assessment report (EPAR): Gazyvaro (updated)
Obinutuzumab, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 22/07/2014,, , Revision: 16, Authorised, Last updated: 20/11/2023
-
List item
Human medicine European public assessment report (EPAR): Tyruko (updated)
natalizumab, Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis
Date of authorisation: 22/09/2023,, 
, Revision: 1, Authorised, Last updated: 20/11/2023
-
List item
Human medicine European public assessment report (EPAR): Mylotarg (updated)
gemtuzumab ozogamicin, Leukemia, Myeloid, Acute
Date of authorisation: 19/04/2018,, Revision: 12, Authorised, Last updated: 20/11/2023
-
List item
Human medicine European public assessment report (EPAR): Kauliv (updated)
teriparatide, Osteoporosis; Osteoporosis, Postmenopausal
Date of authorisation: 12/01/2023,, , Revision: 1, Authorised, Last updated: 20/11/2023
-
List item
Human medicine European public assessment report (EPAR): Lumykras (updated)
sotorasib, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 06/01/2022,, , Revision: 2, Authorised, Last updated: 20/11/2023
-
List item
Human medicine European public assessment report (EPAR): Glivec (updated)
imatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma; Gastrointestinal Stromal Tumors; Dermatofibrosarcoma; Myelodysplastic-Myeloproliferative Diseases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Hypereosinophilic Syndrome
Date of authorisation: 07/11/2001,, Revision: 46, Authorised, Last updated: 20/11/2023
-
List item
Human medicine European public assessment report (EPAR): Artesunate Amivas (updated)
artesunate, Malaria
Date of authorisation: 22/11/2021,, , Revision: 4, Authorised, Last updated: 20/11/2023
-
List item
Human medicine European public assessment report (EPAR): Bimzelx (updated)
bimekizumab, Psoriasis
Date of authorisation: 20/08/2021,, Revision: 5, Authorised, Last updated: 13/11/2023
-
List item
Human medicine European public assessment report (EPAR): Livmarli (updated)
Maralixibat chloride, Alagille Syndrome
Date of authorisation: 09/12/2022,, , , Revision: 3, Authorised, Last updated: 13/11/2023
-
List item
Human medicine European public assessment report (EPAR): Cresemba (updated)
isavuconazole, Aspergillosis
Date of authorisation: 15/10/2015,, Revision: 17, Authorised, Last updated: 13/11/2023
-
List item
Human medicine European public assessment report (EPAR): Lunsumio (updated)
mosunetuzumab, Lymphoma, Follicular
Date of authorisation: 03/06/2022,, , , Revision: 2, Authorised, Last updated: 09/11/2023
-
List item
Human medicine European public assessment report (EPAR): Skyrizi (updated)
Risankizumab, Psoriasis; Arthritis, Psoriatic
Date of authorisation: 26/04/2019,, Revision: 18, Authorised, Last updated: 09/11/2023
-
List item
Human medicine European public assessment report (EPAR): Zirabev (updated)
bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms
Date of authorisation: 14/02/2019,, , Revision: 13, Authorised, Last updated: 09/11/2023
-
List item
Human medicine European public assessment report (EPAR): Oyavas (updated)
bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms
Date of authorisation: 26/03/2021,, , Revision: 6, Authorised, Last updated: 09/11/2023
-
List item
Human medicine European public assessment report (EPAR): Nuceiva (updated)
Botulinum toxin type A, Skin Aging
Date of authorisation: 27/09/2019,, Revision: 5, Authorised, Last updated: 09/11/2023
-
List item
Human medicine European public assessment report (EPAR): Zokinvy (updated)
Lonafarnib, Progeria; Laminopathies
Date of authorisation: 18/07/2022,, , , Revision: 2, Authorised, Last updated: 09/11/2023
-
List item
Human medicine European public assessment report (EPAR): Nuvaxovid (updated)
SARS CoV-2 (Original) recombinant spike protein, SARS-CoV-2 (Omicron XBB.1.5) recombinant spike protein, COVID-19 virus infection
Date of authorisation: 20/12/2021,, Revision: 11, Authorised, Last updated: 08/11/2023